跳至主要内容
临床试验/IRCT20161010030246N6
IRCT20161010030246N6尚未招募3 期

Evaluating the effectiveness of silymarin in preventing vancomycin-induced nephrotoxicity in hospitalized patients

Shiraz University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Hemodynamic stability (mean arterial blood pressure above 70 mmHg and/or systolic blood pressure above 90 mmHg.
  • Willingness to participate in the study
  • Receiving vancomycin intravenously for at least 1 week with the maintenance dosage regimen of 30-45 mg/kg/day or 1-2 g twice a day. Notably, the vancomycin regimen is the same in both hospitals.

排除标准

  • Confirmed history of acute kidney injury
  • Confirmed history of chronic kidney disease
  • Taking vancomycin within the last 14 days
  • Taking silymarin orally at least during the past day
  • Confirmed history of hypersensitivity reactions following oral consumption of silymarin
  • Simultaneous use of agents with antioxidant activity such as vitamin C, vitamin E, vitamin A, melatonin
  • Receiving drugs with high nephrotoxicity potential such as aminoglycosides, amphotericin b, colistin
  • Oral intolerance to drugs

研究者

相似试验